Skip to main content
Equibles
ALZN logo

ALZN · Alzamend Neuro, Inc. · Documents

Track ALZN — free

Use ALZN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ALZN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.30 -0.01 (-0.76%) At close · Nov 12
Rebalance outlook locked
Going-concern doubt — flagged Sep 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors create substantial doubt about our ability to continue as a going concern for at least one year after the date that our condensed financial statements are issued.”
View the 10-Q filed Sep 10, 2026
Market Cap
$6.27M
Shares
4.83M
Volume · Nov 12 23.72K Avg daily vol (3M) 81.99K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2026 Net loss $8.77M 10-K filed Jul 22, 2026 Quarterly report FY2027 Q1 Net loss $3.03M 10-Q filed Sep 10, 2026 Latest results Financial results 8-K filed Jul 23, 2025
2026
Nov 10
Current report 8-K/A Events of Aug 3
Preferred stock financing reduced to $10 million

Alzamend Neuro amended its preferred stock purchase agreement to sell $10 million of Series D Convertible Preferred Stock rather than $25 million, comprising $7.5 million already sold and an additional $2.5 million tranche.

Entered into a material agreement, Unregistered sale of equity, Charter or bylaw amendment, or fiscal year change Read from the first part of this long document
3 source passages
He is the Chief Executive Officer of Alzamend Neuro, Inc., a Delaware corporation (the “Corporation”). According to the A&R Agreement, the Company shall sell to the Purchaser an aggregate of $10 million in Preferred Shares rather than $25 million, of which $7.5 million of Preferred Shares were sold to the Purchaser on the date of the Original Agreement in the Initial Tranche Closing. The A&R Agreement provides that the financing described in the A&R Agreement was and shall be, as applicable, conducted through two (2) separate closings. As provided by the Original Agreement, the Purchaser purchased $7.5 million in Preferred Shares in the Initial Tranche Closing on the Original Execution Date. Pursuant to the A&R Agreement the Company and the Purchaser agreed that the Purchaser shall purchase an additional $2.5 million in Preferred Shares at the second tranche closing (the “**Second Tranche Closing**” and with the Initial Tranche Closing, each a “**Tranche Closing**”). Open the document at this passage
Sep 29
Current report 8-K
Regulation FD disclosure

Dr. Ovidiu C. Andronesi will present Alzamend Neuro’s Phase 1/2A AL001 results at the ISMRT Conference; in healthy participants, trends showed slightly higher brain lithium concentration after AL001 than Li 2 CO 3, but differences were not statistically significant.

Aug 28
Proxy statement PRE 14A Meeting Oct 19, 2026
Proxy statement AI summary on its way
Jul 22
Annual report 10-K FY2026, ended Apr 30
Annual report for FY2026 AI summary on its way
Net loss $8.77M Diluted EPS -$2.63
Jul 21
Current report 8-K
Other events AI summary on its way
Feb 26
Proxy statement DEF 14A Meeting Apr 17, 2026
Proxy statement AI summary on its way
Feb 9
Proxy statement PRE 14A Meeting Apr 17, 2026
Proxy statement AI summary on its way
2025
2024
Showing 1–50 of 126 documents
Key facts CIK 1677077 CUSIP 02262M605 13F (30d) 9 filings 9 filers Visit website Investor relations